Trump reverses planned ban of flavored e-cigarettes

The Trump administration is walking back on its plan to ban flavored e-cigarettes amidst an epidemic of lung illnesses and deaths related to vaping.

The change of direction for the administration came after President Trump was swayed by advisors warning of political backlash about banning the products, The New York Times reported. Action on banning flavored vaping products, which are targeted toward young consumers, appears to have been set aside, according to the NY Times.  

More than 2,000 people have been confirmed across nearly all states to have the illness, known as e-cigarette, or vaping, product use associated lung injury (EVALI), and at least 39 deaths have been reported, according to the CDC. The agency has identified vitamin E acetate as the possible harmful additive in the vaping products, but the exact cause of EVALI is still unknown. Recent studies have indicated vaping could be just as harmful––or more harmful––than smoking traditional cigarettes.

Headlines about the public health crisis caused Trump to first announce a future ban on some vaping products, but e-cigarette loyalists decried that stance. Trump has decided to meet with more groups and stall making a policy decision.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.